Key result
Polymer-free amphilimus-eluting stents yielded similar 2-year device-oriented composite outcomes vs biodegradable-polymer everolimus-eluting stents.
Why the study?
Drug-eluting stents are the standard of care for PCI, but long-term evidence on polymer-free stents remains limited. This study evaluated clinical outcomes of polymer-free amphilimus-eluting stents compared with biodegradable polymer everolimus-eluting stents at 2 years.
Does a polymer-free amphilimus-eluting stent provide noninferior clinical outcomes (device-oriented composite endpoint) compared to a biodegradable polymer everolimus-eluting stent in patients undergoing PCI at 2 years?
RCT (n=2,107)
Assessor-blind
Randomized
Yes
Does a polymer-free amphilimus-eluting stent provide noninferior clinical outcomes (device-oriented composite endpoint) compared to a biodegradable polymer everolimus-eluting stent in patients undergoing PCI at 2 years?
In patients undergoing PCI, polymer-free amphilimus-eluting stents yielded similar 2-year device-oriented clinical outcomes compared to biodegradable polymer everolimus-eluting stents, with a potential late benefit between 1 and 2 years.
Answers are grounded in this paper and cite their sources.
Similar 2-year outcomes support either stent in PCI; leaves open durability beyond 2 years and subgroup effects.
Background Drug-eluting stents are the standard of care for percutaneous coronary intervention (PCI), yet long-term evidence on polymer-free stents remains limited. Aims The aim of this study was to evaluate the clinical outcomes associated with polymer-free amphilimus-eluting stent (PF-AES) compared with biodegradable polymer everolimus-eluting stent (BP-EES) in patients undergoing PCI at 2 years of follow-up. Methods We conducted a randomized, investigator-initiated, assessor-blind, noninferiority trial with minimal exclusion criteria at 14 centers. Patients undergoing PCI were randomized to PF-AES vs. BP-EES. The primary endpoint was a device-oriented composite endpoint (DOCE) of cardiovascular death, target-vessel myocardial infarction, or target-lesion revascularization. Results We included 2,107 patients with 3,042 coronary lesions. At 2-years, DOCE occurred at similar rates between patients randomized to PF-AES vs. BP-EES (10.1% vs. 10.6%, hazard ratio, HR, 0.96, 95% confidence intervals, CI, 0.73-1.25, P = 0.74). Rates of individual DOCE components were comparable, including cardiovascular death (4.2% vs. 3.9%), target-vessel myocardial infarction (5.2% vs. 5.6%), and clinically driven target-lesion revascularization (2.3% vs. 2.6%). Landmark analysis showed a significant interaction between randomized stent and follow-up period (P-interaction=0.025). While DOCE rates were similar from 0 to 1 year (8.2% vs. 7.2%; HR 1.15, 95%CI 0.84-1.56), PF-AES was associated with a lower risk of DOCE between 1 and 2 years compared with BP-EES (2.1% vs. 3.7%; HR 0.56, 95%CI 0.32-0.96). Conclusions In patients undergoing PCI, PF-AES yielded similar outcomes compared to BP-EES at 2-years. The late benefit with PF-AES warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Piccolo et al. (2026) conducted an RCT in Coronary artery disease undergoing percutaneous coronary intervention (PCI) (n=2,107). Polymer-free amphilimus-eluting stent (PF-AES) vs. Biodegradable polymer everolimus-eluting stent (BP-EES) was evaluated on Device-oriented composite endpoint (DOCE) of cardiovascular death, target-vessel myocardial infarction, or target-lesion revascularization (HR 0.96, 95% CI 0.73-1.25, p=0.74). Polymer-free amphilimus-eluting stents yielded similar 2-year device-oriented composite outcomes vs biodegradable-polymer everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: